A Phase 2 Study of Zilovertamab Vedotin With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab (R-CHP) in Diffuse Large B-Cell Lymphoma: waveLINE-007

被引：0

作者：

David, Lavie ^{[1
]}

Muhit, Ozcan ^{[2
]}

Ewa, Paszkiewicz-Kozik ^{[3
]}

Eva, Gonzalez Barca ^{[4
]}

Min, Kim Tae ^{[5
]}

Benedetta, Puccini ^{[6
]}

Siruo, Wang ^{[7
]}

Rushdia, Yusuf ^{[7
]}

Patricia, Marinello ^{[7
]}

Seog, Kim Won ^{[8
]}

机构：

[1] Hadassah Med Ctr, Jerusalem, Israel

[2] Ankara Univ, Sch Med, Ankara, Turkiye

[3] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[4] Barcelona Univ, IDIBELL, Inst Catala Oncol Hosp, Barcelona, Spain

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Azienda Osped Univ Careggi, Florence, Italy

[7] Merck & Co Inc, Rahway, NJ USA

[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-050

引用

页码：S31 / S32

页数：2

共 50 条

[1] waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
Lavie, David
Ozcan, Muhit
Paszkiewicz-Kozik, Ewa
Barca, Eva Gonzalez
Kim, Tae Min
Puccini, Benedetta
Wang, Siruo
Yusuf, Rushdia
Marinello, Patricia
Kim, Won Seog
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
Tilly, Herve
Morschhauser, Franck
Bartlett, Nancy L.
Sharman, Jeff
Haioun, Corinne
Kolibaba, Kathryn S.
Chen, Andy
Lamy, Thierry
Jones, Surai
Penuel, Elicia
Lee, Calvin
Salles, Gilles A.
BLOOD, 2016, 128 (22)
[3] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
Dietrich, S.
Tilly, H.
Morschhauser, F.
Sehn, L. H.
Friedberg, J.
Trneny, M.
Sharman, J. P.
Herbaux, C.
Burke, J. M.
Matasar, M.
Rai, S.
Izutsu, K.
Mehta-Shah, N.
Oberic, L.
Chauchet, A.
Jurczak, W.
Song, Y.
Greil, R.
Mykhalska, L.
Burgues, J. M. B.
Cheung, M. C.
Pinto, A.
Shin, H-J
Hapgood, G.
Munhoz, E.
Abrisqueta, P.
Gau, J-P
Hirata, J.
Jiang, Y.
Yan, M.
Lee, C.
Flowers, C.
Salles, G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
[4] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation
Bartlett, Nancy L.
Chen, Andy I.
Kolibaba, Kathryn S.
Lamy, Thierry
Jones, Surai
Hirata, Jamie
Sharman, Jeff P.
BLOOD, 2015, 126 (23)
[5] POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
Tilly, H.
Sharman, J.
Bartlett, N.
Morschhauser, F.
Haioun, C.
Munoz, J.
Chen, A.
Lamy, T.
Wang, L.
Penuel, E.
Hirata, J.
Lee, C.
Salles, G.
HAEMATOLOGICA, 2017, 102 : 4 - 4
[6] The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta Costa, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher R.
Salles, Gilles
BLOOD, 2021, 138
[7] Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Miguel, Juan
Burgues, Bergua
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher
Salles, Gilles
Collins, Graham
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 14 - 16
[8] Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Flowers, Christopher
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua-Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S358 - S359
[9] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study
Dietrich, Sascha
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yu Qin
Greil, Richard
Mykhalska, Larysa
Bergua Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Salles, Gilles
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 165
[10] The POLARIX Study: Polatuzumab Vedotin With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11

← 1 2 3 4 5 →